KDKathleen B. Digre

Kathleen B. Digre

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kathleen B. Digre has a total of 73 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Use of a Virtual Reality Visual Field Device to Improve Quality of Care in the Emergency Department and Inpatient Setting

    by Aileen G. MacLachlan, Cameron M. Carpenter, Natalie K. Modersitzki, Alison V. Crum, Kathleen B. Digre, Bradley J. Katz, Sravanthi Vegunta, Judith E. A. Warner, Theresa M. Long, Meagan D. Seay

    Background: Automated visual field testing is an essential diagnostic and disease monitoring tool for many neuro-ophthalmic disorders. Most commonly, automated devices are stationary and located in ophthalmology clinics. Thus, formal visual field testing has been limited in the hospital setting until recent availability of virtual reality visual field testing. In this study, we report our experience with the use of a virtual visual field (VVF) device in the Emergency Department (ED) and inpatient hospital settings. Methods: We performed a retrospective chart review of our use of a VVF device in the ED and inpatient hospital setting from February 2020 to September 2022. We report our experience and the impact on patient care with use of the VVF device. Results: One hundred fifty patients (aged 10–85 years) and 162 visual field encounters were identified. Patients were most commonly located on the regular hospital ward (51%), followed by the intensive care unit (28%), and ED (21%). The VVF prevented the need for a trip to the outpatient ophthalmology clinic in 100% of encounters of patients with vision-threatening papilledema. Use of the VVF provided a more detailed, baseline examination at bedside in 61% of all encounters. A bedside pre- and postoperative visual field assessment was achieved in 14% of encounters. The VVF changed management in 70% of encounters. Conclusions: In our experience, use of the VVF has improved the quality of care for inpatients with neuro-ophthalmic conditions. A significant impact of the VVF was increased safety by preventing the need to transport patients to the outpatient setting for visual field monitoring, especially patients with vision-threatening papilledema and lumbar drains. The VVF made formal visual testing available to patients with mobility restrictions and patients undergoing neurosurgical procedures. Owing to improvement in quality of patient care, the VVF analyzer has become a mainstay of the examination of patients in the ED and hospital.

  • NANOSNEWS: European Neuro-Ophthalmology Society Held Its Meeting in Milan, Italy, June 3–6, 2026

    by Judith E. A. Warner, Kathleen B. Digre

    Was not provided for this article.

  • A Scoping Review of Pharmacologic and Nonpharmacologic Interventions to Treat Chronic Ocular Pain

    by Lindsey B. De Lott, Noreen Khan, Mana Yacim, Harini Adivikolanu, Anne Shea, Kate Saylor, Kathleen Digre, Anat Galor

    Background: Chronic ocular pain (COP) is disabling and a common reason for referral to neuro-ophthalmologists. Many patients with COP suffer from amplified or dysfunctional pain processing in the peripheral nervous system (PNS) or central nervous system (CNS), rather than a problem with the eye itself. The extent of and evidence for therapeutic interventions targeting pain in the PNS and CNS among patients suffering from COP are unknown. Evidence Acquisition: We performed a search of Ovid MEDLINE, Embase.com, Scopus.com, and ClinicalTrials.gov. We limited our search to English-language articles published since 2015. We included observational and experimental studies of pharmacologic and nonpharmacologic interventions (e.g., vagal nerve stimulation) used in adults 18 years or older with COP for at least 3 months. Studies were included if the impact on pain intensity, functioning, or quality of life was measured as primary, secondary, or exploratory outcomes. All articles were independently screened by 2 team members for inclusion. Data extraction was performed independently by 2 team members. Any disagreements during the screening and data extraction processes were adjudicated by a third team member and discussed as a group. Results: Our search identified 9,656 studies from 2015 to 2026. Of those, 21 met our inclusion/exclusion criteria. The study designs were mostly retrospective: 5 case reports, 9 observational, and 1 case–control study; 3 prospective studies were nonrandomized, observational studies. Three studies were randomized clinical trials, but one did not have published results. Most of the studies (67%, n = 14) were on pharmacologic interventions including all 3 completed prospective studies. Pharmacologic interventions included gabapentin, cryosim-3 applied to the eyelids, autologous serum tears, botulinum toxin Type A injections, and nerve blocks. The 6 studies including nonpharmacologic interventions used transcutaneous electrical nerve stimulation, trigeminal ganglion stimulation, and pulsed radiofrequency procedures. The 3 randomized controlled clinical trials were of transcutaneous electrical nerve stimulation, topical ocular cooling device, and topical OK-101 ophthalmic solutions at different concentrations. The most common pain measures used across the studies were pain intensity scales (range 0–10), such as the numeric rating scale. Improvements in COP were reported for most studies. The reporting of adverse events occurred in 8 studies (43%). Conclusions: Although COP is a common symptom, we found few studies on pharmacologic and nonpharmacologic treatment interventions with a few randomized controlled trials. Rigorous studies of treatment interventions aimed at reducing COP are needed. We provide recommendations for both the conduct of future studies and the current approach to COP treatment.

  • Persistent aura, visual snow, and other visual symptoms

    by Carrie E Robertson, Kathleen B Digre


  • Open Access

    Short sleep duration and interest in sleep improvement in a multi-ethnic cohort of diverse women participating in a community-based wellness intervention: an unmet need for improvement

    by Sara E. Simonsen, Grant R. Sunada, Kathleen Digre, Louisa A. Stark, Valentine Mukundente, Ed Napia, Fahina Tavake-Pasi, Jeannette Villalta, Doriena Lee, France Davis, et al.

    Background: Disparities in sleep duration are a modifiable contributor to increased risk for cardiometabolic disorders in communities of color. We examined the prevalence of short sleep duration and interest in improving sleep among a multi-ethnic sample of women participating in a culturally tailored wellness coaching program and discussed steps to engage communities in sleep health interventions. Methods: Secondary analysis of data from a randomized trial were used. The wellness coaching trial utilized a Community-Based Participatory Research (CBPR) approach. Data were from the baseline survey and baseline wellness coaching notes. Short sleep duration was defined as < 7 h of self-reported sleep. Participants were prompted to set a goal related to healthy eating/physical activity and had the opportunity to set another goal on any topic of interest. Those who set a goal related to improving sleep or who discussed a desire to improve sleep during coaching were classified as having an interest in sleep improvement. Analyses utilized multivariable models to evaluate factors contributing to short sleep and interest in sleep improvement. We present our process of discussing results with community leaders and health workers. Results: A total of 485 women of color participated in the study. Among these, 199 (41%) reported short sleep duration. In adjusted models, Blacks/African Americans and Native Hawaiians/Pacific Islanders had higher odds of reporting < 7 h of sleep than Hispanics/Latinas. Depression symptoms and self-reported stress management scores were significantly associated with short sleep duration. Interest in sleep improvement was noted in the wellness coaching notes of 52 women (10.7%); sleep was the most common focus of goals not related to healthy eating/physical activity. African Immigrants/Refugees and African Americans were less likely to report interest in sleep improvement. Community leaders and health workers reported lack of awareness of the role of sleep in health and discussed challenges to obtaining adequate sleep in their communities. Conclusion: Despite the high prevalence of short sleep duration, interest in sleep improvement was generally low. This study highlights a discrepancy between need and interest, and our process of community engagement, which can inform intervention development for addressing sleep duration among diverse women.


  • Headache and Eye Pain

    by Kathleen B. Digre, Deborah I. Friedman


  • A Great Conversation With Dr. Shirley Wray

    by Kathleen B. Digre, Rachel A. Calix, Meagan D. Seay

  • Headache and Eye Pain

    by Kathleen B. Digre, Deborah I. Friedman

  • Not All That Flickers Is Snow

    by Rachel C. Patel, Albert T. Vitale, Donnell J. Creel, Kathleen B. Digre

    A woman presented with bilateral visual disturbances that had been diagnosed as visual snow. Dilated ophthalmic examination and multimodal imaging were strongly suggestive of birdshot chorioretinopathy, meriting initiation of systemic immunomodulatory therapy. Visual snow requires a thorough ophthalmologic exam to exclude other ocular diseases.


  • What's New in the Treatment of Migraine?

    by Kathleen B. Digre

    Background: Migraine is very common. In addition to affecting visual quality of life, migraine can be seen in the neuro-ophthalmology office with regularity. Treatment is critical to assist in the reduction of disability and symptoms. Knowing the evidence-based new treatments is important for every neuro-ophthalmologist. Methods: Using PubMed, and using the term migraine as it related to the terms treatment, evidence-based, calcitonin gene-related peptide (CGRP) inhibitor or antibody, electrical stimulation, vagal nerve stimulation, a literature review was performed. Results: Aside from standard well-described and evidence-based therapies for the acute treatment and prevention of migraine, many new therapies have received FDA approval. In this review, we summarize the contribution of new classes of migraine-specific therapies: CGRP antibodies (erenumab, fremanezumab, galcanezumab, and eptinezumab) for prevention and inhibitors referred to as gepants (ubrogepant and rimegepant) for acute treatment. We also cover newer medications about to be approved, such as lasmitiditan. Devices, including the hand-held vagal nerve stimulator, supraorbital stimulation, transmagnetic stimulation, and remote electrical stimulation, are now approved by the FDA for treatment of migraine. Conclusion: Many new and exciting therapies exist for the treatment of migraine. Keeping up with this rapidly evolving field is important in reducing disability from the common disease of migraine.